![]() |
|
|
Vol. 301, Issue 3, 969-974, June 2002
Department of Experimental Clinical Medicine, Ruhr University of
Bochum, Bochum, Germany (B.M.P., K.E.); and Department of Experimental
and Clinical Pharmacology, University of Graz, Graz, Austria (B.A.P.)
This study compares the involvement of ATP-sensitive potassium
(KATP) channels and prostaglandins in various forms of
gastroprotection in the rat. Instillation of 1 ml of 70% ethanol
induced severe gastric mucosal damage (lesion index 39 ± 0.8),
which was substantially but not maximally reduced by oral pretreatment
with 16,16-dimethyl-prostaglandin (PG) E2 (75 ng/kg), 20%
ethanol (1 ml), sodium salicylate (15 mg/kg), the metal salt lithium
chloride (7 mg/kg), the sulfhydryl-blocking agent diethylmaleate (5 mg/kg), and the thiol dimercaprol (10 mg/kg). Administration of
indomethacin (20 mg/kg) increased gastric mucosal damage induced by
70% ethanol (lesion index 45 ± 0.8) and significantly reduced
the protective effect of 20% ethanol, sodium salicylate, lithium
chloride, diethylmaleate, and dimercaprol. The blocker of
KATP channels glibenclamide (5-10 mg/kg) significantly antagonized the protective effect of 16,16-dimethyl-PGE2,
20% ethanol, sodium salicylate, lithium chloride, diethylmaleate, and
dimercaprol. The inhibition of protection induced by glibenclamide was
reversed by pretreatment with the KATP channel activator
cromakalim (0.3-0.5 mg/kg). In conclusion, our results indicate a role
of KATP channels in the gastroprotective effect of
16,16-dimethyl-PGE2 and of the other agents tested. Since
the protection afforded by these agents is additionally
indomethacin-sensitive, it is suggested that under these conditions
endogenous prostaglandins act as activators of KATP
channels, and this mechanism, at least in part, mediates gastroprotection.
This article has been cited by other articles:
![]() |
B. M. Peskar, N. Sawka, K. Ehrlich, and B. A. Peskar Role of Cyclooxygenase-1 and -2, Phospholipase C, and Protein Kinase C in Prostaglandin-Mediated Gastroprotection J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1233 - 1238. [Abstract] [Full Text] [PDF] |
||||